While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward. Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while […]
Edwards Lifesciences
The 10 most popular DeviceTalks Weekly Podcast episodes of 2020
Without the ability to gather for events and meetings, the DeviceTalks team launched the DeviceTalks Weekly Podcast to keep our medtech community talking. Over the span of 9 months and 39 episodes, we interviewed dozens of medtech leaders from startups to multinational corporations to hear how they’re managing through the challenges of 2020. Our episodes […]
Edwards treats first patient in mitral valve disease trial
Edwards Lifesciences (NYSE:EW) announced today that it treated the first patient in a clinical trial for its Harpoon valve repair system. Harpoon is an investigational beating heart mitral valve repair system designed with a less invasive technique than open heart surgery for treating severe degenerative mitral valve regurgitation, according to a news release. Irvine, Calif.-based Edwards […]
Health Canada gives Edwards’ Sapien 3 TAVR expanded use nod
Edwards Lifesciences (NYSE:EW) today announced that Health Canada has approved the expanded use of the company’s Sapien 3 and Sapien 3 Ultra transcatheter heart valves to treat patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. The Sapien 3 valves are the first transcatheter aortic valve replacement (TAVR) systems to […]
MedTech 100 roundup: Stocks stay near last week’s peak
The medtech industry is poised for a big week with the U.S. rollout of the COVID-19 vaccine and stocks remain high from previous peaks. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 100.03 (Dec. 11), marking a minor 0.7% uptick from the 100.75 points […]
Edwards Lifesciences projects TAVR, overall growth in 2021
Edwards Lifesciences (NYSE:EW) is projecting significant growth for 2021, particularly in its transcatheter aortic valve replacement business. Irvine, Calif.-based Edwards is projecting 2021 TAVR sales to represent growth of between 15% and 20% as well as growth in the mid-teens for global sales, the company shared during its investor day presentation. Additionally, Edwards projected adjusted earnings […]
How did medtech companies score on environmental stewardship list?
Medical Design & Outsourcing recently rated the world’s largest medical device companies — the Big 100 — for their sales numbers and R&D spend. Now we can share how some of them scored on an environmental nonprofit’s annual list of companies ranked for their actions on climate change. Not-for-profit organization CDP (Stockholm, Sweden) runs a global disclosure system for […]
Boston Scientific throws in the towel on Lotus TAVR
Boston Scientific (NYSE:BSX) announced today that it has initiated a global, voluntary recall of its Lotus Edge aortic valve system — and is immediately retiring the Lotus program. Marlborough, Mass.-based Boston Scientific said in a news release that the recall of all unused inventory of its Lotus Edge transcatheter aortic valve repair (TAVR) system is due […]
DTW Podcast: Hear the future of AI, 3D, and Dx from Edwards, Stryker, Evercore, Checkable
In this week’s episode of DeviceTalks Weekly we review the Medical Design & Outsourcing’s Women in Medtech issue — bringing you insights through interviews with Katie Syzman, corporate VP and the GM of critical care at Edwards Lifesciences, Naomi Murray, Stryker’s director of advanced operations, and Patty Post, CEO of Startup Checkable Medical. Szyman […]
Edwards reports better-than-expected Q3 results
Edwards Lifesciences (NYSE:EW) shares hardly moved after hours on third-quarter results that came in ahead of the consensus forecast. The Irvine, Calif.-based company posted profits of $325.2 million, or 52¢ per share, on sales of $1.14 billion for the three months ended Sept. 30, 2020, for an 18.4% bottom-line gain on sales growth of 4.3%. Adjusted […]
Abbott beats the Street in Q3, projects higher full-year sales
Abbott (NYSE:ABT) posted stronger-than-expected third-quarter earnings today and upped its full-year projections. The Abbott Park, Ill.-based healthcare giant reported profits of $1.232 billion or 98¢ per share for the quarter ended Sept. 30, 2020, led by a whopping 38.2% increase in global diagnostics sales and a 27% sales jump for diabetes care devices. Analysts had projected […]
